# US 12,006,301 B1 · And synthesis of dual 5-HT1A and 5-HT7 receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,301 B1
- Document ID: US12006301B1
- Status: Granted
- Kind: B1
- Application number: 17/732,018
- Filed: 2022-04-28
- Granted: 2024-06-11
- Earliest claimed: 2021-05-13
- Assignees: Florida A&M University
- Applicants: Florida A&M University
- Inventors: Seth Y. Ablordeppey
- Web page: https://patentgrep.com/patent/US12006301B1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Novel dual 5-HT1A and 5-HT7 receptor ligands and methods of using the novel ligands to treat a neurological disorder are presented.

## Claims

### Claim 1

A compound comprising Formula (I), (II), (III), or (IV):
wherein X is C═O or CH2 and R1 is AcHN or NH2;
wherein R3 is Cl or H;
wherein R4 is Cl, F, I, Br or H;
wherein R5 is CH3 or H;
wherein R6 is ═O, H or OH; and
wherein n is an integer from 1 to 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound comprises Formula (IV).

### Claim 3 (depends on 2)

The compound of claim 2, wherein the R3 is H.

### Claim 4 (depends on 3)

The compound of claim 3, wherein the R4 is Cl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the R5 is CH3.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the R6 is ═O.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the n is 2.

### Claim 8

A composition for treating a neurological disorder comprising:
a compound comprising Formula (I), (II), (III), or (IV):
wherein X is C═O or CH2 and R1 is AcHN or NH2;
wherein R3 is Cl or H;
wherein R4 is Cl, F, I, Br or H;
wherein R5 is CH3 or H;
wherein R6 is ═O, H or OH;
wherein n is an integer from 1 to 3; and
a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the compound comprises Formula (IV).

### Claim 10 (depends on 9)

The composition of claim 9, wherein the R3 is H.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the R4 is Cl.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the R5 is CH3.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the R6 is ═O.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the n is 2.

### Claim 15

A method of treating a neurological disorder in a patient in need thereof comprising:
administering a therapeutically effective amount of a composition to a patient in need thereof, the composition comprising
a compound comprising Formula (I), (II), (III), or (IV):
wherein X is C═O or CH2 and R1 is AcHN or NH2;
wherein R3 is Cl or H;
wherein R4 is Cl, F, I, Br or H;
wherein R5 is CH3 or H;
wherein R6 is ═O, H or OH;
wherein n is an integer from 1 to 3; and
a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurological disorder is selected from the group consisting of depression, anxiety, schizophrenia, and cognitive deficits caused by Alzheimer disease.

### Claim 17 (depends on 15)

The method of claim 15, wherein the compound comprises Formula (IV) wherein the R3 is H and the R4 is Cl.

### Claim 18 (depends on 17)

The method of claim 17, wherein the R5 is CH3.

### Claim 19 (depends on 18)

The method of claim 18, wherein the R6 is ═O.

### Claim 20 (depends on 19)

The method of claim 19, wherein the n is 2.